p. 2151−2153
2476-762X
Vol.14/No.4
p. 2155−2157
2476-762X
Vol.14/No.4
p. 2159−2165
2476-762X
Vol.14/No.4
p. 2167−2172
2476-762X
Vol.14/No.4
p. 2173−2179
2476-762X
Vol.14/No.4
p. 2181−2184
2476-762X
Vol.14/No.4
p. 2185−2190
2476-762X
Vol.14/No.4
p. 2191−2199
2476-762X
Vol.14/No.4
p. 2201−2205
2476-762X
Vol.14/No.4
p. 2207−2212
2476-762X
Vol.14/No.4
p. 2213−2216
2476-762X
Vol.14/No.4
p. 2217−2220
2476-762X
Vol.14/No.4
p. 2221−2224
2476-762X
Vol.14/No.4
p. 2225−2229
2476-762X
Vol.14/No.4
50%) in Indian breast cancer patients, underlining the need for effective diagnostic screening and specific therapeutic managements in order to improve the survival rate of patients in low resource countries such as India.]]>
p. 2231−2235
2476-762X
Vol.14/No.4
p. 2237−2242
2476-762X
Vol.14/No.4
p. 2243−2248
2476-762X
Vol.14/No.4
0.05). In conclusion, Tualang Honey exertedpositive modulation effects on DMBA-induced breast cancers in rats in this preliminary study.]]>
p. 2249−2254
2476-762X
Vol.14/No.4
p. 2255−2258
2476-762X
Vol.14/No.4
p. 2259−2263
2476-762X
Vol.14/No.4
p. 2265−2268
2476-762X
Vol.14/No.4
G) Polymorphism and Digestive System Cancer Risk]]>
G) and digestive system cancer risk have remained inconclusive. To better understandthe role of the MMP-7 (-181A>G) genotype in digestive cancer development, we conducted this comprehensivemeta-analysis encompassing 3,518 cases and 4,596 controls. Overall, the MMP-7 (-181A>G) polymorphism wasassociated with higher digestive system cancer risk on homozygote comparison (GG vs. AA, OR=1.21, 95% CI =1.12-1.60) and in a dominant model (GG/GA vs. AA, OR=1.16, 95% CI =1.03-1.46). On subgroup analysis, thispolymorphism was significantly linked to higher risks for gastric cancer (GG vs. AA, OR=1.22, 95% CI = 1.02-1.46; GA vs. AA, OR=1.82, 95% CI =1.16-2.87; GG/GA vs. AA, OR=1.13, 95% CI =1.01-1.27; GG vs. GA/AA,OR= 1.25, 95% CI = 1.06-2.39. We also observed increased susceptibility to colorectal cancer and esophagealSCC in both homozygote (OR = 1.13, 95% CI = 1.06-1.26) and heterozygote comparisons (OR = 1.45, 95% CI= 1.11-1.91). In the stratified analysis by controls, significant effects were only observed in population-basedstudies (GA vs. AA, OR=1.16, 95% CI=1.08-1.50; GA/AA vs. GG, OR=1.10, 95% CI=1.01-1.72). According to thesource of ethnicity, a significantly increased risk was found among Asian populations in the homozygote model(GG vs. AA, OR=1.40, 95% CI=1.12–1.69), heterozygote model (GA vs. AA, OR=1.26, 95% CI=1.02–1.51), anddominant model (GG/GA vs. AA, OR=1.18, 95% CI=1.08–1.55). Our findings suggest that the MMP-7 (-181A>G)polymorphism may be a risk factor for digestive system cancer, especially among Asian populations.]]>
p. 2269−2272
2476-762X
Vol.14/No.4
p. 2273−2276
2476-762X
Vol.14/No.4
55 compared to age group≤ 45), but not that of ultrasonography. Neither breast density nor volume had significant effect on sensitivityof mammography or ultrasonography. Conclusions: Ultrasonography is more sensitive than mammography indetecting breast cancer in women under 55 year-old Chinese, especially in those with high-density and relativelysmall breasts.]]>
p. 2277−2282
2476-762X
Vol.14/No.4
p. 2283−2288
2476-762X
Vol.14/No.4
p. 2289−2293
2476-762X
Vol.14/No.4
p. 2295−2299
2476-762X
Vol.14/No.4
p. 2301−2305
2476-762X
Vol.14/No.4
p. 2307−2310
2476-762X
Vol.14/No.4
p. 2311−2315
2476-762X
Vol.14/No.4
p. 2317−2323
2476-762X
Vol.14/No.4
p. 2325−2331
2476-762X
Vol.14/No.4
p. 2333−2336
2476-762X
Vol.14/No.4
p. 2337−2342
2476-762X
Vol.14/No.4
p. 2343−2347
2476-762X
Vol.14/No.4
p. 2349−2354
2476-762X
Vol.14/No.4
p. 2355−2359
2476-762X
Vol.14/No.4
p. 2361−2366
2476-762X
Vol.14/No.4
p. 2367−2370
2476-762X
Vol.14/No.4
p. 2371−2375
2476-762X
Vol.14/No.4
0.05). Among 166 patients who received postoperativeadjuvant therapy in the three groups, the occurrence rates were: 65.4%, 64.3% and 61.1% respectively formyelosuppression; 42.3%, 38.1%, and 38.9% for nausea and vomiting; 9.6%, 9.5% and 9.7% for urocystitis;and 63.5%, 69.0% and 65.3% enteritis and rectitis. There were no statistically significant differences amongthem (all P>0.05). The five-year disease-free survival rates (DFS) in groups 1, 2, 3 were 78.3%, 75.1%, 80.9%,respectively; the five-year overall survival rates (OS) were 81.4%, 78.2%, and 81.1%, respectively. The five-yearOS of 166 patients receiving postoperative in the three groups were 72.4%, 69.5%, and 71.8%, respectively, withno significant variation (all P>0.05). Although there were no differences among three groups in DFS and OS,preoperative neoadjuvant chemotherapy combined with intracavitary radiotherapy may increase the effectiverate and the percentage of patients with no postoperative risk factors and decrease the percentage of patientsreceiving postoperative adjuvant therapy, thereby decreasing complications indirectly and increasing qualityof life.]]>
p. 2377−2381
2476-762X
Vol.14/No.4
0.05, although it remained unclear whetherthere was a relationship between positive cases and clinical diagnostic data.]]>
p. 2383−2386
2476-762X
Vol.14/No.4
p. 2387−2391
2476-762X
Vol.14/No.4
p. 2393−2399
2476-762X
Vol.14/No.4
p. 2401−2406
2476-762X
Vol.14/No.4
p. 2407−2412
2476-762X
Vol.14/No.4
p. 2413−2419
2476-762X
Vol.14/No.4
p. 2421−2427
2476-762X
Vol.14/No.4
p. 2429−2432
2476-762X
Vol.14/No.4
p. 2433−2437
2476-762X
Vol.14/No.4
p. 2439−2442
2476-762X
Vol.14/No.4
p. 2443−2446
2476-762X
Vol.14/No.4
p. 2447−2451
2476-762X
Vol.14/No.4
p. 2453−2459
2476-762X
Vol.14/No.4
p. 2461−2476
2476-762X
Vol.14/No.4
p. 2477−2481
2476-762X
Vol.14/No.4
p. 2483−2486
2476-762X
Vol.14/No.4
p. 2487−2490
2476-762X
Vol.14/No.4
p. 2491−2494
2476-762X
Vol.14/No.4
p. 2495−2502
2476-762X
Vol.14/No.4
p. 2503−2508
2476-762X
Vol.14/No.4
5 cm in size received RT. Regionalnodal irradiation was not applied. Systemic chemotherapy was given to 105 patients (92.9%). Patient data wereretrospectively reviewed and analyzed to identify predictive factors for SCLR. Results: The median follow-upduration was 6.5 years, with 5- and 10-year actuarial SCLR rates of 9.3% and 11.2%, respectively. Factorsassociated with SCLR on univariate analysis included histologic grade, number of dissected axillary lymph nodes,lymphovascular invasion, extracapsular extension (ECE), and adjuvant chemotherapy. On multivariate analysis,histologic grade and ECE remained significant. The patient group with grade 3 and ECE had a significantlyhigher rate of SCLR compared with the remainder (5-year SCLR rate; 71.4% vs. 4.0%, p<0.001). Conclusions:Histologic grade and ECE status are significant predictive factors for SCLR. Supraclavicular nodal RT isnecessary in N1 breast cancer patients featuring histologic grade 3 and ECE.]]>
p. 2509−2514
2476-762X
Vol.14/No.4
p. 2515−2519
2476-762X
Vol.14/No.4
p. 2521−2523
2476-762X
Vol.14/No.4
p. 2525−2528
2476-762X
Vol.14/No.4
p. 2529−2532
2476-762X
Vol.14/No.4
p. 2533−2540
2476-762X
Vol.14/No.4
0.05). Conclusions: We conclude that NSE may be applied in routine togain insight about the clinical statuses of various cancer patients, but more studies are needed to determine theorgan specificity.]]>
p. 2541−2544
2476-762X
Vol.14/No.4
p. 2545−2549
2476-762X
Vol.14/No.4
p. 2551−2555
2476-762X
Vol.14/No.4
p. 2557−2561
2476-762X
Vol.14/No.4
p. 2563−2566
2476-762X
Vol.14/No.4
p. 2567−2670
2476-762X
Vol.14/No.4
p. 2571−2575
2476-762X
Vol.14/No.4
C and IL10-1082 A>G polymorphismswere determined by Sequenom MassARRAY analysis. Results: Patients with GC reported statistically higherproportions of family history of cancer (29.9% versus 10.7%, P<0.01) and alcohol drinking (54.6% versus 43.2%,P<0.01) than did controls. Similar results were observed in comparison between non-cardia GC patients andcontrols (PC and IL10-1082 A>G were not associated withoverall GC risk (adjusted OR, 0.94, 95% CI, 0.66-1.33; adjusted OR, 1.00, 95% CI, 0.62-1.60). Sub-analysisshowed that the IL10-592 AC/CC variant genotype was associated with decreased non-cardia GC risk (adjustedOR, 0.58; 95% CI, 0.36-0.95). No association was found between any of the IL10 haplotypes established fromtwo polymorphisms and risk of non-cardia GC. Conclusions: In conclusion, our data do not link the two SNPs ofIL10-592 and IL10-1082 with overall GC risk. We demonstrate that IL10-592 polymorphism is associated withprotective effect against non-cardia GC. Our findings may offer insight into risk associated with the developmentof GC in this region.]]>
p. 2577−2582
2476-762X
Vol.14/No.4
p. 2583−2589
2476-762X
Vol.14/No.4
0.05). No significant differences were detected in hematologic and neurologic toxicities between thetwo groups (P>0.05). However, nausea, vomiting and hypersensitive reactions were significantly lower in groupA than in group B (P<0.05). Conclusion: Paclitaxel liposomes are as effective as paclitaxel when combined withtegafur and oxaliplation in treating patients with advanced gastric cancer, but adverse reactions with paclitaxelliposomes are less common.]]>
p. 2591−2594
2476-762X
Vol.14/No.4
70 years’ respectively. Non-diabetic (70%),hypertensive (74%), with family history (80%) of cancer, with localized-disease (91%) and treated with surgery,either alone or in combination, (91%) had better survival. Conclusions: The present study showed that prostatecancer patients with localized disease at diagnosis experience a better outcome. Local treatment with eithersurgery or radiation achieves a reasonable outcome in prostate cancer patients. A detailed study will help inunderstanding the prognostic indicators for survival especially with the newer treatment technologies availablenow.]]>
p. 2595−2598
2476-762X
Vol.14/No.4
p. 2599−2605
2476-762X
Vol.14/No.4
p. 2607−2610
2476-762X
Vol.14/No.4
p. 2611−2614
2476-762X
Vol.14/No.4
p. 2615−2619
2476-762X
Vol.14/No.4
p. 2621−2626
2476-762X
Vol.14/No.4
p. 2627−2630
2476-762X
Vol.14/No.4
p. 2631−2635
2476-762X
Vol.14/No.4
p. 2637−2641
2476-762X
Vol.14/No.4
p. 2643−2647
2476-762X
Vol.14/No.4
p. 2649−2656
2476-762X
Vol.14/No.4
2mm) and 18 micrometastases (<2mm). The overall sensitivity and specificityof frozen section analysis of SLN for the detection of macrometastasis was found to be 100% while those formicrometastasis were 33.3% and 100%, respectively. Moreover 20% of patients who had micrometastases inSLN had positive non-SLNs on final histology. Conclusions: Frozen section analysis of SLNs lacks sufficientaccuracy to rule out micrometastasis by current protocols. Therefore these need to be revised in order to pick upmicrometastasis which appears to have clinical significance. We suggest that this can be achieved by examiningmore step sections of blocks.]]>
p. 2657−2662
2476-762X
Vol.14/No.4
p. 2663−2665
2476-762X
Vol.14/No.4
p. 2667−2671
2476-762X
Vol.14/No.4
p. 2673−2680
2476-762X
Vol.14/No.4
p. 2681−2684
2476-762X
Vol.14/No.4
p. 2685−2686
2476-762X
Vol.14/No.4
C and 499C>T Polymorphisms in Skin Cancer]]>
p. 2687−2688
2476-762X
Vol.14/No.4